Evidence given to parliamentary committee sparks new calls to develop national capability to manufacture medicines and key supplies
Australian companies were “shocked” to experience price-gouging and had trouble accessing critical supplies to make medicines and personal protective equipment at the height of the pandemic, a parliamentary committee has been told.
It has prompted fresh calls for Australia to build up its ability to manufacture critical drugs “without reliance on opaque and fragile offshore supply chains”.
Related: Paracetamol and Ventolin limited to one per customer as Australia combats coronavirus hoarding
Related: Australia needs a national centre for disease control, peak doctors’ group says
